Dapirolizumab

• Description:

  Dapirolizumab is a monoclonal antibodi against CD40 ligand. Dapirolizumab targets CD40L, blocks its interaction with CD40 receptors, and inhibits adaptive immune activation. Dapirolizumab attenuates systemic lupus erythematosus[1].

• UNSPSC:

  12352203

• Target:

  TNF Receptor

• Type:

  Inhibitory Antibodies

• Related Pathways:

  Apoptosis

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/dapirolizumab.html

• Purity:

  99.66

• Smiles:

  [Dapirolizumab]

• Molecular Weight:

  (145.5 kDa)

• References & Citations:

  [1]Furie RA, et al., Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus. Rheumatology (Oxford) . 2021 Nov 3;60 (11) :5397-5407.

• Shipping Conditions:

  Dry Ice

• Storage Conditions:

  Store at -80°C for 2 years

• Scientific Category:

  Inhibitory Antibodies

• Clinical Information:

  Phase 3

• CAS Number:

  [1416147-64-2]